

September 2, 2026

SymBio Pharmaceuticals Limited
 Fuminori Yoshida
 Representative Director,
 President and Chief Executive Officer
 Keiichi Fujiwara
 Interim CFO
 TEL: +81-3-5472-1125

Notice Regarding Completion of the Acquisition and Cancellation of the 58th, 66th, and 67th Stock Acquisition Rights and Completion of Payment of the Issue Price for the 70th and 71st Stock Acquisition Rights (with Exercise Price Adjustment Clauses) through Third-Party Allotment

SymBio Pharmaceuticals Limited (the “Company”) hereby announces the following with respect to two matters resolved at the meeting of its Board of Directors held on August 17, 2026. First, the acquisition and cancellation of all of the 58th Stock Acquisition Rights issued through third-party allotment on June 1, 2022 (the “58th Stock Acquisition Rights”) that remained outstanding as of August 17, 2026, and all of the 66th and 67th Stock Acquisition Rights issued through third-party allotment on August 12, 2025 (the “66th Stock Acquisition Rights” and the “67th Stock Acquisition Rights,” respectively) that remained outstanding as of August 31, 2026, have been completed. Second, the Company confirmed that payment of the total issue price of ¥2,880,000 for the 70th and 71st Stock Acquisition Rights issued to EVO FUND (“EVO FUND” or the “Allottee”) (the “70th Stock Acquisition Rights” and the “71st Stock Acquisition Rights,” respectively, and individually or collectively, the “Stock Acquisition Rights”) was completed on September 2, 2026.

For details regarding the acquisition and cancellation of the 58th, 66th, and 67th Stock Acquisition Rights and the issuance of the Stock Acquisition Rights, please refer to the “Notice Regarding the Execution of an Unsecured Bond Facility Agreement, the Issuance of the 2nd Unsecured Straight Bonds (Private Placement), the Issuance of the 70th and 71st Stock Acquisition Rights (with Exercise Price Adjustment Clauses) through Third-Party Allotment, the Execution of a Purchase Agreement for the Stock Acquisition Rights (Commit Issue), and the Acquisition and Cancellation of the 58th, 66th, and 67th Stock Acquisition Rights” announced on August 17, 2026.

<Overview of the Acquisition and Cancellation of the 58th, 66th, and 67th Stock Acquisition Rights>

(1) Names of the Stock Acquisition Rights Acquired and Cancelled	SymBio Pharmaceuticals Limited’s 58th Stock Acquisition Rights SymBio Pharmaceuticals Limited’s 66th Stock Acquisition Rights SymBio Pharmaceuticals Limited’s 67th Stock Acquisition Rights
(2) Total Number of Stock Acquisition Rights Issued	58th Stock Acquisition Rights: 20,000 units (2,000,000 shares) 66th Stock Acquisition Rights: 200,000 units (20,000,000 shares) 67th Stock Acquisition Rights: 100,000 units (10,000,000 shares)
(3) Number of Stock Acquisition Rights Exercised	58th Stock Acquisition Rights: 0 units (0 shares) 66th Stock Acquisition Rights: 79,490 units (7,949,000 shares) 67th Stock Acquisition Rights: 0 units (0 shares)
(4) Number of Stock Acquisition Rights Acquired and Cancelled	58th Stock Acquisition Rights: 20,000 units (2,000,000 shares) 66th Stock Acquisition Rights: 120,510 units (12,051,000 shares) 67th Stock Acquisition Rights: 100,000 units (10,000,000 shares)
(5) Acquisition Price	Aggregate acquisition price: ¥14,903,570 58th Stock Acquisition Rights: aggregate amount of ¥13,760,000 (¥688 per Stock Acquisition Right) 66th Stock Acquisition Rights: aggregate amount of ¥843,570 (¥7 per Stock Acquisition Right)

	67th Stock Acquisition Rights: aggregate amount of ¥300,000 (¥3 per Stock Acquisition Right)
(6) Acquisition Date and Cancellation Date	58th Stock Acquisition Rights Acquisition date: August 18, 2026 Cancellation date: September 1, 2026 66th and 67th Stock Acquisition Rights Acquisition date: August 31, 2026 Cancellation date: September 1, 2026
(7) Number of Stock Acquisition Rights Remaining after Cancellation	0

<Overview of the Stock Acquisition Rights>

(1) Allotment Date	September 2, 2026
(2) Number of Stock Acquisition Rights to be Issued	960,000 units 70th Stock Acquisition Rights: 480,000 units 71st Stock Acquisition Rights: 480,000 units
(3) Issue Price	Total of ¥2,880,000 ¥4 for each unit of the 70th Stock Acquisition Rights ¥2 for each unit of the 71st Stock Acquisition Rights
(4) Potential Shares from the Issuance	96,000,000 shares (100 shares per unit of Stock Acquisition Rights) 70th Stock Acquisition Rights: 48,000,000 shares 71st Stock Acquisition Rights: 48,000,000 shares There is no upper limit on the exercise price. The lower limit of the exercise price is set at ¥36. Even in the case where the exercise price reaches this lower limit, the total number of potential shares remains 96,000,000.
(5) Total Funds to Be Raised	¥6,768,880,000 (Note)
(6) Exercise Price and Conditions for Adjustment of Exercise Price	The initial exercise price is ¥71. (1) The exercise price will first be adjusted on the second trading day (inclusive) following the allotment date (where “trading day” refers to a day on which trading is conducted on the Tokyo Stock Exchange; the same applies hereinafter). Thereafter, the exercise price will be adjusted every trading day. Each date on which such an adjustment occurs is referred to individually or collectively as an “Adjustment Date.” When the exercise price is adjusted under this clause, it shall be revised on the Adjustment Date to an amount equal to 100% of the closing price of the Company’s common shares in regular trading on the Tokyo Stock Exchange on the trading day immediately preceding the Adjustment Date (the “Reference Date”; such revised price, the “Revised Exercise Price”). However, if the resulting Revised Exercise Price is lower than the minimum exercise price, it shall be deemed equal to the minimum exercise price. If no closing price is available on the relevant Reference Date, no adjustment will be made. In addition, if an event giving rise to an adjustment under Item 11 of the Terms and Conditions of Issuance of the Stock Acquisition Rights occurs on a Reference Date, the closing price of the Company’s common shares in regular trading announced by

	the Tokyo Stock Exchange for that Reference Date shall be adjusted to reflect such event. (2) Notwithstanding item (1) of this paragraph, the exercise price shall not be adjusted during either of the following periods: (i) the period from the trading day immediately preceding a shareholder record date or similar date relating to the Company's common shares, inclusive, through such shareholder record date or similar date, inclusive, during which the Stock Acquisition Rights cannot be exercised for procedural reasons relating to the Japan Securities Depository Center, Inc. (the "Shareholder Record Period"; provided, however, that if the Japan Securities Depository Center, Inc. changes such period, the revised period shall apply); or (ii) the trading day immediately following the final day of the Shareholder Record Period. In such case, the next adjustment of the exercise price shall be made on the second trading day following the final day of the Shareholder Record Period, inclusive, and thereafter the exercise price shall be adjusted in accordance with item (1) of this paragraph each time one trading day has elapsed. (3) Notwithstanding items (1) and (2) of this paragraph, if an exercise of the Stock Acquisition Rights would constitute a Restricted Excess Exercise as defined in Article 436, Paragraph 1 of the Enforcement Rules for Securities Listing Regulations of the Tokyo Stock Exchange, and the exercise price applicable to such exercise as calculated pursuant to items (1) and (2) of this paragraph would be lower than the closing price of the Company's common shares in regular trading announced by the Tokyo Stock Exchange on August 17, 2026 (subject to fair and reasonable adjustment in the event of a stock split, gratis allotment, or consolidation of the Company's common shares after the issuance of the Stock Acquisition Rights; the "Closing Price on the Issue Resolution Date"), then the exercise price applicable to such exercise shall be revised to an amount equal to the Closing Price on the Issue Resolution Date.
(7) Method of Offering or Allotment (Allottee)	All of the Stock Acquisition Rights will be allotted to EVO FUND through a third-party allotment.
(8) Exercise Period	From September 3, 2026 to September 3, 2029
(9) Other Terms	(1) On August 17, 2026, the Company entered into the Purchase Agreement with the Allottee, which includes the exercise commitment clause for the 70th Stock Acquisition Rights, a provision that the Allottee may not exercise the 71st Stock Acquisition Rights until the date designated by the Company on or after the trading day immediately following the Company's instruction to commence exercise, as well as provisions requiring approval by resolution of the Company's Board of Directors if the Allottee transfers any of the Stock Acquisition Rights, among other matters. On September 2, 2026, the Company also entered into a total subscription agreement with the Allottee. (2) If the Company's Board of Directors resolves that it is necessary to acquire the Stock Acquisition Rights, the Company may, on or after the date falling one month after the payment date for the Stock Acquisition

	Rights, acquire all or part of the Stock Acquisition Rights remaining outstanding on the acquisition date designated by the Board of Directors (the “Acquisition Date”), in accordance with Articles 273 and 274 of the Companies Act, by giving notice to the holders of the Stock Acquisition Rights (the “Holders”) or their affiliates at least two weeks prior to the Acquisition Date; provided, however, that if such notice is not received by the Holders or their affiliates by 4:00 p.m. on the relevant day, the notice shall be deemed to have been given on the following trading day. The acquisition price shall be equal to the amount paid per Stock Acquisition Right, multiplied by the number of Stock Acquisition Rights to be acquired, with any fraction of less than one yen rounded to the nearest yen. If the Company acquires only part of the Stock Acquisition Rights, the rights to be acquired shall be selected by lottery or another reasonable method. (3) On September 3, 2029, the Company shall acquire all of the Stock Acquisition Rights held by the Holders other than the Company at a price of ¥4 per 70th Stock Acquisition Right and ¥2 per 71st Stock Acquisition Right.
--	---

(Note) The amount of funds to be raised is calculated by adding the total amount of the payment for the Stock Acquisition Rights and the total value of the assets to be contributed upon the exercise of the Stock Acquisition Rights (calculated based on the initial exercise price), and then subtracting the estimated total expenses associated with the issuance of the Stock Acquisition Rights. If the exercise price is revised or adjusted, the amount of funds to be raised may increase or decrease accordingly. Furthermore, the total value of the assets to be contributed upon the exercise of the Stock Acquisition Rights is based on the assumption that all Stock Acquisition Rights are exercised at the initial exercise price, and the actual amount of funds raised may vary depending on market conditions at the time of exercise. In addition, if the Stock Acquisition Rights are not exercised during the exercise period or if Stock Acquisition Rights acquired by the Company are cancelled, the amount of funds to be raised will fluctuate.